Strengthening the Value of Managed Care and Specialty Pharmacy for Successful Management of Hemophilia

• Release date: March 31, 2017
• Expiration date: September 30, 2018
• Estimated Time to Complete Activity: 1.0 hours
• Compatible with all modern browsers and mobile devices

DISTINGUISHED FACULTY

Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsulting Hartford, Connecticut Click here for biography Vanita K. Pindolia, PharmD, BCPS Vice President, Ambulatory Clinical Pharmacy Programs_PCM Henry Ford Health System/Health Alliance Plan of Michigan Detroit, Michigan Click here for biography Steven Pipe, MD Director, Division of Pediatric Hematology and Oncology Pediatric Medical Director Hemophilia and Coagulation Disorders Program University of Michigan Ann Arbor, Michigan Click here for biography Michael Zeglinski, RPh Senior Vice President, Specialty Pharmacy OptumRx®/BriovaRx® Pittsburgh, Pennsylvania Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, and nurses

Statement of Need/Program Overview
For health plans, treatment for patients with bleeding disorders, especially those with hemophilia, can be a tremendously heavy financial burden. The treatment of hemophilia ranks among the most expensive chronic diseases in the United States. New technology has led to remarkable advances in improving the safety of new blood products, but these technologies have come at ever-increasing costs. Total annual costs depend upon the severity of the disease and can average $250,000 or more for severe patients. Complications such as major surgery, undergoing immune tolerance for an inhibitor, HIV/AIDS, and/or hepatitis treatments, can increase these costs exponentially.

The high cost of clotting factor concentrates and the even higher cost of treatment of inhibitors makes hemophilia a potential target for cost-cutting efforts by various payers. Optimal outcomes for patients with hemophilia require a collaborative and coordinated patient experience. Representatives of the comprehensive care team, including a managed care medical director, managed care pharmacy director, specialty pharmacy expert, and a Hemophilia Treatment Center (HTC) clinician, will highlight important opportunities to optimize costs and improve patient care.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Describe current and evolving strategies for managed care organizations (MCOs) and specialty pharmacy providers to facilitate high quality care for members with hemophilia
• Cite the most recent clinical recommendations for the treatment of patients with hemophilia, including prophylactic factor replacement and the role of emerging agents
• Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
• Identify processes for MCOs and specialty pharmacy providers to improve communications with Hemophilia Treatment Centers (HTCs)
• Apply methods to enable optimal cost management of factor replacement therapy to be realized by MCOs and specialty pharmacy providers

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources Inc. (MER), National Hemophilia Foundation, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources Inc. (MER) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Medical Education Resources Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-9999-17-086-H01-P.

Type of Activity
This activity is certified as Knowledge-based CPE.

Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Alnylam Pharmaceuticals, Baxalta, part of Shire, Bayer HealthCare Pharmaceuticals Inc., Grifols, and Novo Nordisk, Inc.. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Impact Education, LLC, and/or Alnylam Pharmaceuticals, Baxalta, part of Shire, Bayer HealthCare Pharmaceuticals Inc., Grifols, and Novo Nordisk, Inc. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period March 31, 2017 through September 30, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.